DPT0415

DPT0415 is a highly potent, selective, and orally administered small molecule inhibitor of **Lipoprotein-associated phospholipase A2 (Lp-PLA2)**, developed as a **novel scaffold**. It is designed primarily as a **disease-modifying therapy for diabetic retinopathy (DR) and diabetic macular edema (DME)**. DPT0415 exhibits superior potency, safety profile, and absorption/distribution/metabolism/excretion (ADME) properties compared to existing Lp-PLA2 inhibitors such as darapladib. Preclinical studies demonstrate robust efficacy in rat models of STZ-induced diabetic retinopathy, with target engagement at a low dose (0.3 mpk). The mechanism of action targets Lp-PLA2, an enzyme contributing to vascular inflammation and blood-retinal barrier (BRB) damage; by inhibiting Lp-PLA2, DPT0415 may reduce inflammation and vascular leakage, potentially improving vision and offering a less invasive alternative to current anti-VEGF therapies for DME/DR. The drug was nominated and developed using the RiDYMO platform by DP Technology, integrating AI-based simulation and experimental approaches[1][2][3][6].

Other names

DPT-0415DPT0415DPT 0415